Abstract:Class I HDACs are considered promising targets for cancer due to their role in epigenetic modifications. The main challenges in developing a new, potent and non-toxic class I HDAC inhibitor are selectivity and appropriate pharmacokinetics. The PROTAC technique (Proteolysis Targeting Chimera) is a new method in drug development for the production of active substances that can degrade a protein of interest (POI) instead of inhibiting it. This technique will open the era to produce selective and potent drugs with a high margin of safety. Previously, we reported different inhibitors targeting class I HDACs functionalized with aminobenzamide or hydroxamate groups. In the current research work, we will employ PROTAC technique to develop class I HDAC degraders based on our previously reported inhibitors. We synthesized two series of aminobenzamide-based PROTACs and hydroxamate-based PROTACs and tested them in vitro against class I HDACs. To ensure their degradation, all of them were screened against HDAC2 as representative example of class I. The best candidates were evaluated at different concentrations at various HDAC subtypes. This resulted in the PROTAC (32a) (HI31.1) that degrades HDAC8 with a DC50 of 8.9 nM with a proper margin of selectivity against other isozymes. Moreover, PROTAC 32a is able to degrade HDAC6 with DC50 = 14.3 nM. Apoptotic study on leukemic cells (MV-4-11) displayed more than 50 % apoptosis took place at 100 nM. PROTAC 32a (HI31.1) showed a good margin of safety against normal cell line and proper chemical stability.

Discovery of Selective Proteolysis-Targeting Chimera Degraders Targeting PTP1B as Long-Term Hypoglycemic Agents

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Discovery and Evaluation of the Hybrid of Bromophenol and Saccharide As Potent and Selective Protein Tyrosine Phosphatase 1B Inhibitors

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases

Discovery of Inhibitors Targeting Protein Tyrosine Phosphatase 1B Using a Combined Virtual Screening Approach

Developing selective PI3K degraders to modulate both kinase and non-kinase functions

Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Discovery of a Selective TC-PTP Degrader for Cancer Immunotherapy

Identification of natural product inhibitors of PTP1B based on high-throughput virtual screening strategy: In silico, in vitro and in vivo studies

Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain

Targeting UBE2C for Degradation by Bioprotacs Based on Bacterial E3 Ligase